Literature DB >> 9636358

Adenovirus VAI RNA antagonizes the RNA-editing activity of the ADAR adenosine deaminase.

M Lei1, Y Liu, C E Samuel.   

Abstract

The virus-associated VAI RNA of adenovirus is a small highly structured RNA that is required for the efficient translation of cellular and viral mRNAs at late times after infection. VAI RNA antagonizes the activation of the interferon-inducible RNA-dependent protein kinase, PKR, an important regulator of translation. The RNA-specific adenosine deaminase, ADAR, is an interferon-inducible RNA-editing enzyme that catalyzes the site-selective C-6 deamination of adenosine to inosine. ADAR possesses three copies of the highly conserved RNA-binding motif (dsRBM) that are similar to the two copies found in PKR, the enzyme in which the prototype dsRBM motif was discovered. We have examined the effect of VAI RNA on ADAR function. VAI RNA impairs the activity of ADAR deaminase. This inhibition can be observed in extracts prepared from interferon-treated human cells and from monkey COS cells in which wild-type recombinant ADAR was expressed. Analysis of wild-type and mutant forms of VA RNA suggests that the central domain is important in the antagonism of ADAR activity. These results suggest that VAI RNA may modulate viral and cellular gene expression by modulating RNA editing as well as mRNA translation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9636358     DOI: 10.1006/viro.1998.9162

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  23 in total

1.  Chimeric double-stranded RNA-specific adenosine deaminase ADAR1 proteins reveal functional selectivity of double-stranded RNA-binding domains from ADAR1 and protein kinase PKR.

Authors:  Y Liu; M Lei; C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 2.  Activity regulation of adenosine deaminases acting on RNA (ADARs).

Authors:  Cesare Orlandi; Alessandro Barbon; Sergio Barlati
Journal:  Mol Neurobiol       Date:  2011-11-20       Impact factor: 5.590

3.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 4.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

5.  A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus.

Authors:  Roland C Zahn; Ina Schelp; Olaf Utermöhlen; Dorothee von Laer
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

6.  Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis.

Authors:  Ping Zhang; Bertram L Jacobs; Charles E Samuel
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

Review 7.  Tipping the balance: antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products.

Authors:  Cyril X George; Zhiqun Li; Kristina M Okonski; Ann M Toth; Ying Wang; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

Review 8.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

9.  Persistent growth of a human plasma-derived hepatitis C virus genotype 1b isolate in cell culture.

Authors:  Erica Silberstein; Kathleen Mihalik; Laura Ulitzky; Ewan P Plant; Montserrat Puig; Sara Gagneten; Mei-ying W Yu; Neerja Kaushik-Basu; Stephen M Feinstone; Deborah R Taylor
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

Review 10.  Rotavirus and reovirus modulation of the interferon response.

Authors:  Barbara Sherry
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.